Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : vitamins herbs supplements longevity and aging -- Ignore unavailable to you. Want to Upgrade?

To: E. Charters who wrote (7259)	6/8/2009 9:33:24 AM
From: Solon	Read Replies (1) \| Respond to of 17090

content.nejm.org "First, insulin-sensitizing therapy was associated with fewer secondary end points than the use of insulin, especially among patients undergoing CABG. Second, as compared with optimal medical therapy, patients who underwent CABG (but not PCI) had significantly fewer major cardiac events, an important finding that was driven mainly by a reduction in nonfatal myocardial infarction. Although it is essential to stress that BARI 2D was not designed to directly compare long-term outcomes between PCI and CABG, the differences in secondary end points render indirect comparisons likely."